Agilent Technologies Stock

$125.21

0.36%

NYSE, Sep 02, 10:00 pm CET

ISIN

US00846U1016

Symbol

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Life Sciences Tools & Services

Overview Dividends Analysts Charts News Strategies

Agilent Technologies Stock price

$125.21

+21.79 21.07% 5Y

NYSE, Closing price Tue, Sep 02 2025

-0.45 0.36%

ISIN

US00846U1016

Symbol

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Life Sciences Tools & Services

Key metrics

Basic

Market capitalization

$35.5b

Enterprise Value

$37.5b

Net debt

$2.0b

Cash

$1.5b

Shares outstanding

283.9m

Valuation (TTM | estimate)

P/E

30.6 | 22.0

P/S

5.4 | 5.1

EV/Sales

5.7 | 5.4

EV/FCF

31.5

P/B

5.8

Dividends

DPS

$0.94

Yield 1Y | 5Y

0.8% | 0.7%

Growth 1Y | 5Y

4.9% | 7.6%

Payout 1Y | 3Y

21.3% | 21.0%

Increased

13 Years

Financials (TTM | estimate)

Revenue

$6.6b | $6.9b

EBITDA

$1.8b | $2.1b

EBIT

$1.5b | $1.8b

Net Income

$1.2b | $1.6b

Free Cash Flow

$1.2b

Growth (TTM | estimate)

Revenue

0.6% | 6.3%

EBITDA

13.6% | 13.0%

EBIT

14.8% | 14.7%

Net Income

-6.1% | 25.3%

Free Cash Flow

-22.7%

Financial Health

Equity Ratio

49.8%

Return on Equity

21.9%

ROCE

15.2%

ROIC

13.8%

Debt/Equity

0.6

EPS

$4.1

FCF per Share

$4.2

Short interest

1.2%

Employees

18k

Rev per Employee

$360.0k

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Get Started for Free Today

Agilent Technologies Stock Analysis

Unlock Scores for Free

??

26 Analysts have issued a Agilent Technologies forecast:

14x Buy

54%

12x Hold

46%

More details on Analyst Estimates Including Price Targets

26 Analysts have issued a Agilent Technologies forecast:

Buy

54%

Hold

46%

Analyst Estimates with Stock Price Targets

Financial data from Agilent Technologies

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Apr '25		+/- %
Revenue	6,628 6,628	1% 1% 100%
- Direct Costs	3,064 3,064	6% 6% 46%
Gross Profit	3,564 3,564	6% 6% 54%
- Selling and Administrative Expenses	1,577 1,577	2% 2% 24%
- Research and Development Expense	441 441	2% 2% 7%
EBITDA	1,823 1,823	14% 14% 28%
- Depreciation and Amortization	277 277	7% 7% 4%
EBIT (Operating Income) EBIT	1,546 1,546	15% 15% 23%
Net Profit	1,166 1,166	6% 6% 18%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Agilent Technologies Stock News

Neutral

Business Wire

●

about 24 hours ago

Agilent's MMR IHC Panel pharmDx (Dako Omnis) Receives European IVDR Certification as a Companion Diagnostic Test for Colorectal Cancer

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer. MMR IHC Panel pharmDx (Dako Omnis) is indicated as an aid to identify mismatch repair (MMR) deficient CRC patients e...

Positive

Seeking Alpha

●

6 days ago

Agilent: Growth Across All Segments, But Investors Will Need To Be Patient

Agilent Technologies, Inc.'s Q3 2025 earnings beat expectations, with revenue up 10% YoY and GAAP EPS rising 22%, despite margin contraction across all segments. Management raised full-year 2025 guidance, projecting 6.35% revenue growth and higher non-GAAP EPS, signaling confidence in continued business momentum. The company returned over $150M to shareholders through buybacks and dividends, de...

Neutral

Seeking Alpha

●

6 days ago

Agilent Technologies, Inc. (A) Q3 2025 Earnings Call Transcript

Agilent Technologies, Inc. (NYSE:A ) Q3 2025 Earnings Conference Call August 27, 2025 4:30 PM ET Company Participants Angelica A. Riemann - Senior VP & President of Agilent CrossLab Group Jian Miao Zhang - Senior VP & President of Applied Markets Group Padraig McDonnell - CEO, President & Director Parmeet Ahuja - Vice President of Investor Relations Rodney Gonsalves - Interim CFO, Principal Acc...

More Agilent Technologies News

Company Profile

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Head office	United States
CEO	Padraig Mcdonnell
Employees	17,900
Founded	1999
Website	www.agilent.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now